Thus, the CALR-activated dendritic cells have potent activity in priming anti-tumor cytotoxic CD8+ T lymphocytes (CTLs) and CALR is a potential molecular target in anti-tumor immunotherapy (30–32). Here, CD8A is linked to neoplasm.